Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company’s full-year revenue guidance of $1.57 billion at the midpoint came in 1.8% below analysts’ estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts’ consensus estimates.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 22.2% in the afternoon session after the company reported weak first quarter 2025 results which included a significant miss on full-year EPS guidance and EPS falling short of Wall Street's estimates. Sales were flat, with a slight drop in PYLARIFY mostly offset by small gains in other parts of the business. Operating profit also fell. The real issue was the cut to full-year earnings, now seen at $6.60 to $6.70 per share, well below the $7.00 to $7.20 range it gave before. Overall, this was a softer quarter.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company’s full-year revenue guidance of $1.57 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts’ consensus estimates.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
will be announcing earnings results tomorrow before market open. Here’s what you need to know.
LANTHEUS HOLDINGS INC could be undervalued. NASDAQ:LNTH is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - imaging, diagnostics stocks fared in Q4, starting with Hologic (NASDAQ:HOLX).
Discover LANTHEUS HOLDINGS INC, an undervalued growth gem. NASDAQ:LNTH is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns,
and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including QuidelOrtho (NASDAQ:QDEL) and its peers.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at GE HealthCare (NASDAQ:GEHC) and its peers.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 9.1%. This drop was worse than the S&P 500’s 1.8% loss.
Discover LANTHEUS HOLDINGS INC, an undervalued growth gem. NASDAQ:LNTH is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including Lantheus (NASDAQ:LNTH) and its peers.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
jumped 19.8% in the morning session after the company delivered strong fourth-quarter 2024 results, with revenue and earnings topping analysts' expectations. Sales rose 10.5% year-on-year, fueled by high demand for its radiopharmaceutical products, including PYLARIFY, which crossed $1 billion in annual sales.
For 2025, the company set a bullish earnings forecast, well above consensus estimates. However, its full-year revenue outlook came in slightly below expectations, pointing to a more cautious growth path.
Overall, the quarter was decent, showcasing areas of strength in key product lines while highlighting some challenges, particularly in balancing revenue growth with increased spending on future initiatives.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.5% year on year to $391.1 million. On the other hand, the company’s full-year revenue guidance of $1.58 billion at the midpoint came in 2.3% below analysts’ estimates. Its non-GAAP profit of $1.59 per share was 3% above analysts’ consensus estimates.
